

Roger Stupp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5020947/publications.pdf>

Version: 2024-02-01

103
papers

43,893
citations

76031

42
h-index

56606

87
g-index

110
all docs

110
docs citations

110
times ranked

34052
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602. | 3.2 | 67 |
| 2 | Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071â€“22072 and CORE Trials. <i>Clinical Cancer Research</i> , 2022, 28, 129-136. | 3.2 | 25 |
| 3 | Leptomeningeal metastases: the future is now. <i>Journal of Neuro-Oncology</i> , 2022, 156, 443-452. | 1.4 | 11 |
| 4 | Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1533-1545. | 0.6 | 13 |
| 5 | The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1269-1278. | 0.4 | 20 |
| 6 | Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. <i>Neuro-Oncology</i> , 2022, 24, 2159-2169. | 0.6 | 7 |
| 7 | Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 3156-3169. | 3.2 | 4 |
| 8 | Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, . | 0.4 | 1 |
| 9 | Role of Resection in Glioblastoma Management. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 9-22. | 0.8 | 14 |
| 10 | Activation of 4-1BBL+ B cells with CD40 agonism and IFNÎ³ elicits potent immunity against glioblastoma. <i>Journal of Experimental Medicine</i> , 2021, 218, . | 4.2 | 42 |
| 11 | Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. <i>Neuro-Oncology</i> , 2021, 23, 1327-1336. | 0.6 | 15 |
| 12 | PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. <i>Molecular Cell</i> , 2021, 81, 1276-1291.e9. | 4.5 | 54 |
| 13 | <i>De novo</i> purine biosynthesis is a major driver of chemoresistance in glioblastoma. <i>Brain</i> , 2021, 144, 1230-1246. | 3.7 | 30 |
| 14 | <i>MGMT</i> promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas. <i>Neuro-Oncology</i> , 2021, 23, 858-860. | 0.6 | 8 |
| 15 | Tumor type, epilepsy burden, and seizure documentation: experiences at a single center neuro-oncology clinic. <i>Neuro-Oncology Practice</i> , 2021, 8, 581-588. | 1.0 | 0 |
| 16 | Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. <i>Lancet Oncology</i> , The, 2021, 22, 1103-1114. | 5.1 | 91 |
| 17 | EXTH-36. ELECTROCONVULSIVE SEIZURE-INDUCED CHANGES IN THE TUMOR MICROENVIRONMENT PROMOTE SURVIVAL IN GLIOMA-BEARING MICE. <i>Neuro-Oncology</i> , 2021, 23, vi171-vi171. | 0.6 | 0 |
| 18 | BIOM-31. ERK1/2 PHOSPHORYLATION PREDICTS SURVIVAL FOLLOWING ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi17-vi17. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | INNV-13. UNDERSTANDING FACTORS THAT INFLUENCE THE DECISION OF ACCEPTING TUMOR TREATING FIELDS (TTF) THERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi107-vi108. | 0.6 | 0 |
| 20 | ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. <i>Nature Cancer</i> , 2021, 2, 1372-1386. | 5.7 | 39 |
| 21 | CTNI-47. INTERIM RESULTS OF NCT03011671: A MULTI-INSTITUTIONAL PHASE I STUDY OF ACETAZOLAMIDE WITH TEMOZOLOMIDE IN ADULTS WITH NEWLY DIAGNOSED MGMT-METHYLATED MALIGNANT GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi70-vi70. | 0.6 | 1 |
| 22 | IMMU-29. B-CELL-BASED VACCINE PRODUCES GLIOBLASTOMA-REACTIVE ANTIBODIES THAT CONTRIBUTE TO TUMOR CLEARANCE. <i>Neuro-Oncology</i> , 2021, 23, vi98-vi98. | 0.6 | 0 |
| 23 | BIOM-32. ENDOPLASMIC RETICULUM PROTEIN SSR3 DETERMINES AND PREDICTS RESPONSE TO PACLITAXEL IN BREAST CANCER AND GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi17-vi18. | 0.6 | 0 |
| 24 | EXTH-29. DUAL TGFB AND PD1 BLOCKADE PROMOTES GERMINAL-CENTER B-CELL IMMUNE RESPONSES AGAINST GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi169-vi169. | 0.6 | 1 |
| 25 | Ultrasound-mediated Blood-brain barrier opening increases cell-free DNA in a time dependent manner. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab165. | 0.4 | 5 |
| 26 | CTIM-12. A PHASE 1 TRIAL OF IMMUNORADIOTHERAPY WITH THE IDO ENZYME INHIBITOR (BMS-986205) AND NIVOLUMAB IN PATIENTS WITH NEWLY DIAGNOSED MGMT PROMOTER UNMETHYLATED IDHwt GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi51-vi52. | 0.6 | 3 |
| 27 | TMOD-08. DEVELOPING DERIVATIVE GBM PDX, IN VIVO, FROM TREATMENT NAÏVE SOURCES. <i>Neuro-Oncology</i> , 2021, 23, vi217-vi217. | 0.6 | 0 |
| 28 | Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. <i>International Journal of Cancer</i> , 2020, 146, 803-809. | 2.3 | 42 |
| 29 | Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. <i>Neuro-Oncology</i> , 2020, 22, 470-479. | 0.6 | 49 |
| 30 | Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations. <i>Clinical Cancer Research</i> , 2020, 26, 477-486. | 3.2 | 98 |
| 31 | Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. <i>Neuro-Oncology Practice</i> , 2020, 7, 668-675. | 1.0 | 5 |
| 32 | Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , 2020, 9, 8373-8385. | 1.3 | 19 |
| 33 | Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue. <i>BMC Cancer</i> , 2020, 20, 458. | 1.1 | 0 |
| 34 | Ribosomal protein S11 influences glioma response to TOP2 poisons. <i>Oncogene</i> , 2020, 39, 5068-5081. | 2.6 | 21 |
| 35 | cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020, 139, 603-608. | 3.9 | 344 |
| 36 | Temporal activation of WNT/ β -catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. <i>Oncogene</i> , 2020, 39, 4132-4154. | 2.6 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Leptomeningeal metastasis from solid tumors. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116706. | 0.3 | 34 |
| 38 | Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa147. | 0.4 | 1 |
| 39 | CTNI-31. INTERIM RESULTS OF A PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BBB OPENING WITH THE SONOCLOUD-9 IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO IV CARBOPLATIN. <i>Neuro-Oncology</i> , 2020, 22, ii49-ii49. | 0.6 | 1 |
| 40 | Are Integrins Still Practicable Targets for Anti-Cancer Therapy?. <i>Cancers</i> , 2019, 11, 978. | 1.7 | 128 |
| 41 | Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , 2019, 21, 1447-1457. | 0.6 | 35 |
| 42 | The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508. | 0.6 | 49 |
| 43 | The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019, 116, 190-198. | 1.3 | 22 |
| 44 | Overcoming the Blood-Brain Barrier with an Implantable Ultrasound Device. <i>Clinical Cancer Research</i> , 2019, 25, 3750-3752. | 3.2 | 18 |
| 45 | Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 90-100. | 0.4 | 20 |
| 46 | ACTR-57. A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH A NINE-EMITTER IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO CARBOPLATIN. <i>Neuro-Oncology</i> , 2019, 21, vi26-vi27. | 0.6 | 0 |
| 47 | CMET-11. RESPONSE TO STEREOTACTIC RADIOSURGERY FOR MULTIPLE BRAIN METASTASES BASED ON HISTOLOGY-SPECIFIC SUBTYPE STATUS. <i>Neuro-Oncology</i> , 2019, 21, vi53-vi53. | 0.6 | 0 |
| 48 | QOLP-03. MEASURING CHANGE IN HEALTH-RELATED QUALITY OF LIFE: THE ADDED VALUE OF ANALYSIS ON THE INDIVIDUAL PATIENT LEVEL IN GLIOMA PATIENTS IN CLINICAL DECISION MAKING. <i>Neuro-Oncology</i> , 2019, 21, vi197-vi198. | 0.6 | 1 |
| 49 | QOLP-04. CALCULATING THE NET CLINICAL BENEFIT IN BRAIN TUMOR TRIALS BY COMBINING SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE DATA USING TWO METHODS: QUALITY ADJUSTED SURVIVAL EFFECT SIZES AND JOINT MODELLING. <i>Neuro-Oncology</i> , 2019, 21, vi198-vi198. | 0.6 | 0 |
| 50 | MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. <i>Neuro-Oncology</i> , 2019, 21, 167-178. | 0.6 | 173 |
| 51 | Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. <i>Journal of Neuro-Oncology</i> , 2019, 141, 111-120. | 1.4 | 24 |
| 52 | Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). <i>Journal of Thoracic Oncology</i> , 2019, 14, 115-123. | 0.5 | 21 |
| 53 | <i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1809-1816. | 3.2 | 94 |
| 54 | IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 2559-2573. | 3.2 | 147 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018, 136, 153-166. | 3.9 | 298 |
| 56 | The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018, 135, 601-615. | 3.9 | 76 |
| 57 | Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2018, 4, 495. | 3.4 | 135 |
| 58 | CAR T-Cell Therapies in Glioblastoma: A First Look. <i>Clinical Cancer Research</i> , 2018, 24, 535-540. | 3.2 | 103 |
| 59 | QOLP-29. SYMPTOM CLUSTERS IN NEWLY DIAGNOSED GLIOMA PATIENTS: WHICH CLUSTERS ARE ASSOCIATED WITH FUNCTIONING AND GLOBAL HEALTH STATUS?. <i>Neuro-Oncology</i> , 2018, 20, vi221-vi221. | 0.6 | 0 |
| 60 | QOLP-11. QUALITY OF LIFE IN HIGH-GRADE GLIOMA PATIENTS ON A PHASE I VIROTHERAPY STUDY. <i>Neuro-Oncology</i> , 2018, 20, vi216-vi216. | 0.6 | 1 |
| 61 | CSIG-18. MODELING TEMOZOLOMIDE RESISTANCE WITH GLIOBLASTOMA PATIENT DERIVED XENOGRAPTS. <i>Neuro-Oncology</i> , 2018, 20, vi46-vi47. | 0.6 | 0 |
| 62 | ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA), Tj ETQq0.0 0 rgBTi/Overlock | 0.6 | 0 |
| 63 | CSIG-35. MST4 PHOSPHORYLATION OF ATG4B REGULATES ALTOPHAGIC ACTIVITY, TUMORIGENICITY, AND RADIORESISTANCE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi50-vi51. | 0.6 | 0 |
| 64 | cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". <i>Acta Neuropathologica</i> , 2018, 136, 805-810. | 3.9 | 599 |
| 65 | B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma. <i>Diagnostic Pathology</i> , 2018, 13, 37. | 0.9 | 7 |
| 66 | European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , The, 2017, 18, e315-e329. | 5.1 | 816 |
| 67 | The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017, 19, 625-635. | 0.6 | 137 |
| 68 | Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017, 19, 1119-1126. | 0.6 | 107 |
| 69 | Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385. | 5.1 | 776 |
| 70 | Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. <i>Clinical Cancer Research</i> , 2017, 23, 6650-6660. | 3.2 | 141 |
| 71 | Evidence-based management of adult patients with diffuse glioma " Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e430-e431. | 5.1 | 5 |
| 72 | Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet</i> , The, 2017, 390, 1645-1653. | 6.3 | 307 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. <i>Cancer Cell</i> , 2017, 32, 840-855.e8. | 7.7 | 188 |
| 74 | Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e709-e710. | 5.1 | 5 |
| 75 | Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2306. | 3.8 | 1,619 |
| 76 | IMMU-22. COMBINATION IMMUNOTHERAPY WITH IDO1 INHIBITION ENHANCES TREATMENT EFFICACY IN MULTIPLE MODELS OF GLIOBLASTOMA MODEL. <i>Neuro-Oncology</i> , 2017, 19, vi117-vi117. | 0.6 | 0 |
| 77 | Corticosteroids compromise survival in glioblastoma. <i>Brain</i> , 2016, 139, 1458-1471. | 3.7 | 271 |
| 78 | Phase II Study of Radiotherapy and Temozolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016, 22, 4797-4806. | 3.2 | 105 |
| 79 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2016, 17, 1521-1532. | 5.1 | 396 |
| 80 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2535. | 3.8 | 982 |
| 81 | Chromosome 7 gain and DNA hypermethylation at the <i>HOXA10</i> locus are associated with expression of a stem cell related <i>HOX</i> -signature in glioblastoma. <i>Genome Biology</i> , 2015, 16, 16. | 3.8 | 82 |
| 82 | Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. <i>Lancet</i> , The, 2015, 386, 1049-1056. | 6.3 | 316 |
| 83 | Withholding temozolomide in glioblastoma patients with unmethylated <i>MGMT</i> promoter – still a dilemma?: Table 1.. <i>Neuro-Oncology</i> , 2015, 17, 1425-1427. | 0.6 | 78 |
| 84 | Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma – First report of the full dataset of the EF14 randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2000-2000. | 0.8 | 16 |
| 85 | Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2006-2006. | 0.8 | 7 |
| 86 | The accuracy of predicting survival in individual patients with cancer. <i>Journal of Neurosurgery</i> , 2014, 120, 24-30. | 0.9 | 113 |
| 87 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1100-1108. | 5.1 | 800 |
| 88 | PET Imaging in Glioma. <i>PET Clinics</i> , 2013, 8, 117-128. | 1.5 | 4 |
| 89 | Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 916-926. | 5.1 | 1,075 |
| 90 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. <i>Lancet Oncology</i> , The, 2009, 10, 459-466. | 5.1 | 6,451 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. <i>Lancet Oncology</i> , The, 2009, 10, 785-793. | 5.1 | 106 |
| 92 | Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. <i>Journal of Clinical Oncology</i> , 2007, 25, 4127-4136. | 0.8 | 474 |
| 93 | Anaplastic astrocytoma in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 63, 72-80. | 2.0 | 67 |
| 94 | Neuro-oncology: oligodendroglioma and molecular markers. <i>Lancet Neurology</i> , The, 2007, 6, 10-12. | 4.9 | 6 |
| 95 | Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for Glioblastoma Multiforme. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2006, 1, 37-52. | 0.0 | 2 |
| 96 | Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma. <i>Oncologist</i> , 2006, 11, 165-180. | 1.9 | 357 |
| 97 | Optimal role of temozolomide in the treatment of malignant gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 198-206. | 2.0 | 168 |
| 98 | MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. <i>New England Journal of Medicine</i> , 2005, 352, 997-1003. | 13.9 | 6,573 |
| 99 | Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. <i>New England Journal of Medicine</i> , 2005, 352, 987-996. | 13.9 | 17,395 |
| 100 | Small cell lung cancer: state of the art and future perspectives. <i>Lung Cancer</i> , 2004, 45, 105-117. | 0.9 | 150 |
| 101 | Prognostic factors for low-grade gliomas. <i>Seminars in Oncology</i> , 2003, 30, 23-28. | 0.8 | 52 |
| 102 | Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide. <i>Journal of Clinical Oncology</i> , 2002, 20, 1375-1382. | 0.8 | 703 |
| 103 | Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiforme. , 0, , 37-52. | | 1 |